...Absolutely. Thanks for having me, and it's great to chat again. So Rocket Pharma is a gene therapy company. We're a multi-platform or platform-agnostic gene therapy company, whichever way we like to think about it. Multi-platform in the sense that we focus on both in vivo AAV gene therapy as well as ex vivo antiviral gene therapy. And we're also open to other platforms in the future, so truly a multi-platform approach or platform-agnostic approach. Our thesis in selection of disease types, disease organs and disease areas and specific diseases is that there are a large number of rare diseases, of course, in the world, and many of those rare disease have a very clear, on-target mechanism of action. And the mechanism of action here for all these diseases centers around a particular protein where a little protein could go a long way. And we try to target the cell of interest, in that sense that, for example, in Danon disease, the cardiomyocyte is a primary cell of interest and the protein...
